Details of the Drug

General Information of Drug (ID: DM2C48U)

Drug Name
Anisindione
Synonyms
Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione
Indication
Disease Entry ICD 11 Status REF
Coagulation defect 3B10.0 Approved [1], [2]
Therapeutic Class
Anticoagulants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 252.26
Topological Polar Surface Area (xlogp) 2.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C16H12O3
IUPAC Name
2-(4-methoxyphenyl)indene-1,3-dione
Canonical SMILES
COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
InChI
InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
InChIKey
XRCFXMGQEVUZFC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2197
ChEBI ID
CHEBI:133809
CAS Number
117-37-3
DrugBank ID
DB01125
TTD ID
D09WKB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Anisindione (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Anisindione caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Clarithromycin DM4M1SG Major Decreased metabolism of Anisindione caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Ticarcillin DM4ME02 Moderate Increased risk of bleeding by the combination of Anisindione and Ticarcillin. Bacterial infection [1A00-1C4Z] [16]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Anisindione caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Esterified estrogens DM9KZDO Moderate Antagonize the effect of Anisindione when combined with Esterified estrogens. Breast cancer [2C60-2C6Y] [18]
Fenofibric acid DMGO2MC Major Increased plasma concentration of Anisindione and Fenofibric acid due to competitive binding of plasma proteins. Cardiovascular disease [BA00-BE2Z] [19]
Chenodiol DMQ8JIK Moderate Increased risk of bleeding by the combination of Anisindione and Chenodiol. Cholelithiasis [DC11] [20]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Anisindione and Levomilnacipran. Chronic pain [MG30] [21]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Anisindione and Regorafenib. Colorectal cancer [2B91] [22]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Anisindione and Intedanib. Colorectal cancer [2B91] [23]
Mestranol DMG3F94 Moderate Antagonize the effect of Anisindione when combined with Mestranol. Contraceptive management [QA21] [24]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Anisindione and Ardeparin. Coronary thrombosis [BA43] [25]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Anisindione and Rivaroxaban. Deep vein thrombosis [BD71] [26]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Anisindione and Vilazodone. Depression [6A70-6A7Z] [21]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Anisindione and Vortioxetine. Depression [6A70-6A7Z] [21]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Anisindione and Milnacipran. Depression [6A70-6A7Z] [21]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Anisindione and Escitalopram. Depression [6A70-6A7Z] [21]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Anisindione and Desvenlafaxine. Depression [6A70-6A7Z] [21]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Anisindione and Clomipramine. Depression [6A70-6A7Z] [21]
[3H]estrone-3-sulphate DMGPF0N Moderate Antagonize the effect of Anisindione when combined with [3H]estrone-3-sulphate. Discovery agent [N.A.] [24]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Anisindione and Apigenin. Discovery agent [N.A.] [27]
Fosphenytoin DMOX3LB Moderate Increased risk of bleeding by the combination of Anisindione and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [28]
Phenobarbital DMXZOCG Major Increased metabolism of Anisindione caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Anisindione caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Itraconazole DMCR1MV Moderate Decreased metabolism of Anisindione caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [30]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Anisindione caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [17]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Anisindione and Avapritinib. Gastrointestinal stromal tumour [2B5B] [22]
PSI-7977 DMLSUWZ Moderate Antagonize the effect of Anisindione when combined with PSI-7977. Hepatitis virus infection [1E50-1E51] [31]
Simeprevir DMLUA9D Moderate Antagonize the effect of Anisindione when combined with Simeprevir. Hepatitis virus infection [1E50-1E51] [22]
Daclatasvir DMSFK9V Moderate Antagonize the effect of Anisindione when combined with Daclatasvir. Hepatitis virus infection [1E50-1E51] [22]
Etravirine DMGV8QU Moderate Decreased metabolism of Anisindione caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Gemfibrozil DMD8Q3J Major Increased plasma concentration of Anisindione and Gemfibrozil due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [19]
Amobarbital DM0GQ8N Major Increased metabolism of Anisindione caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [33]
Proguanil DMBL79I Moderate Decreased metabolism of Anisindione caused by Proguanil mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [34]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Anisindione and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [35]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Anisindione and Acalabrutinib. Mature B-cell lymphoma [2A85] [36]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Anisindione and Ibrutinib. Mature B-cell lymphoma [2A85] [31]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Anisindione and Ponatinib. Mature B-cell lymphoma [2A85] [37]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Anisindione and Panobinostat. Multiple myeloma [2A83] [14]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Anisindione and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [38]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Anisindione and Prasugrel. Myocardial infarction [BA41-BA43] [22]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Anisindione and Vorapaxar. Myocardial infarction [BA41-BA43] [39]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Anisindione and Nepafenac. Osteoarthritis [FA00-FA05] [40]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Anisindione caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [41]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Anisindione and MK-4827. Ovarian cancer [2C73] [22]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Anisindione and Choline salicylate. Postoperative inflammation [1A00-CA43] [42]
Enzalutamide DMGL19D Moderate Increased metabolism of Anisindione caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Estramustine DMWTAOI Moderate Antagonize the effect of Anisindione when combined with Estramustine. Prostate cancer [2C82] [24]
Bicalutamide DMZMSPF Minor Increased plasma concentration of Anisindione and Bicalutamide due to competitive binding of plasma proteins. Prostate cancer [2C82] [43]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Anisindione and Epoprostenol. Pulmonary hypertension [BB01] [44]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Anisindione and Salsalate. Rheumatoid arthritis [FA20] [45]
Armodafinil DMGB035 Moderate Decreased metabolism of Anisindione caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [14]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Anisindione and Curcumin. Solid tumour/cancer [2A00-2F9Z] [46]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Anisindione and Caplacizumab. Thrombocytopenia [3B64] [14]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Anisindione and Apixaban. Thrombosis [DB61-GB90] [22]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Anisindione and Cangrelor. Thrombosis [DB61-GB90] [47]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Anisindione and Brilinta. Thrombosis [DB61-GB90] [22]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Anisindione and Cabozantinib. Thyroid cancer [2D10] [48]
Lixisenatide DM0QJDC Minor Altered absorption of Anisindione due to GI dynamics variation caused by Lixisenatide. Type 2 diabetes mellitus [5A11] [14]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Anisindione and Betrixaban. Venous thromboembolism [BD72] [47]
Propafenone DMPIBJK Moderate Decreased metabolism of Anisindione caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [49]
⏷ Show the Full List of 61 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6960).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010909.
3 Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
4 Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
5 New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
6 New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
7 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
8 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
11 Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
12 Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
13 Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
14 Cerner Multum, Inc. "Australian Product Information.".
15 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126(3 Suppl) (2004): 204S-233S. [PMID: 15383473]
16 Alexander DP, Russo ME, Fohrman DE, Rothstein G "Nafcillin-induced platelet dysfunction and bleeding." Antimicrob Agents Chemother 23 (1983): 59-62. [PMID: 6830209]
17 Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
18 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58. [PMID: 4397794]
19 Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997): 615-33. [PMID: 9339964]
20 Product Information. Chenodal (chenodeoxycholic acid). Manchester Pharmaceutical, Fort Collins, CO.
21 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
22 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
23 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
24 Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
25 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
26 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
27 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
28 Hansen JM, Siersboek-Nielsen K, Skovsted L "Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man." Clin Pharmacol Ther 12 (1971): 539-43. [PMID: 5567804]
29 Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022]
30 Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
31 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
32 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
33 Antlitz AM, Tolentino M, Kosai MF "Effect of butabarbital on orally administered anticoagulants." Curr Ther Res Clin Exp 10 (1968): 70-3. [PMID: 4967727]
34 Product Information. Malarone (atovaquone-proguanil) Glaxo Wellcome, Research Triangle Pk, NC.
35 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
36 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
38 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
39 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
40 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
41 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
42 Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
43 Product Information. Casodex (bicalutamide). Zeneca Pharmaceuticals, Wilmington, DE.
44 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
45 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
46 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
47 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
48 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
49 Kates RE, Yee YG, Kirsten EB "Interaction between warfarin and propafenone in healthy volunteer subjects." Clin Pharmacol Ther 42 (1987): 305-11. [PMID: 3621785]